The contract implementing the 'Value in Prescribing' savings measure shows the Department of Health requires the consortium to promote non-bDMARD treatments directly to consumers to support its target of generating $50 million in savings. …
Contract requires 'direct to consumer' promotion of cheap alternatives
October 21, 2021 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Government moves on general co-pay as safety gets further out of reach
July 29, 2025 - - Latest News -
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech -
US and EU secure new trade agreement, but 'more to come' on pharmaceuticals
July 28, 2025 - - Latest News -
Leading stakeholders call for urgency on national genomics framework
July 28, 2025 - - Latest News -
Hepatitis Australia wants action as new analysis reveals many still missing cures
July 28, 2025 - - Latest News